Today: 13 May 2026
Browse Category

Pharmaceuticals 22 July 2025 - 22 August 2025

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······
Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

On July 2, 2025, the FDA granted accelerated approval to linvoseltamab for relapsed/refractory multiple myeloma and approved sunvozertinib as the first targeted oral therapy for advanced NSCLC with EGFR exon 20 insertion mutations. The FDA also cleared denosumab biosimilars for osteoporosis, and Senegal was declared free of trachoma by the WHO.
22 July 2025
·
1 … 38 39 40

Stock Market Today

  • Analog Devices (ADI) Stock Valuation Assessment Amid Strong Price Gains
    May 13, 2026, 2:53 PM EDT. Analog Devices (ADI) stock has surged nearly 20% in the past 30 days and delivered an 87.95% total shareholder return over one year, drawing investor attention. The stock trades at $419.65, about 6.8% above its modeled fair value of $392.94, indicating potential overvaluation. Drivers include growth from robotics and automation expanding ADI's addressable market and boosting revenue. However, risks remain from increased competition in China and rising manufacturing and R&D costs that could pressure margins. Investors should weigh ADI's growth potential against these challenges when considering inclusion in portfolios.

Latest articles

Palantir Stock Slides as Zelenskiy Meeting Puts War-AI Bet in Focus

Palantir Stock Slides as Zelenskiy Meeting Puts War-AI Bet in Focus

13 May 2026
Palantir shares fell 4.4% to $129.97 Wednesday as CEO Alex Karp met President Volodymyr Zelenskiy in Kyiv to discuss expanding AI use in Ukraine’s war effort. Kyiv’s Brave1 Dataroom project, launched with Palantir, is training AI models to intercept Russian drones. Russia fired at least 800 drones at Ukraine on Wednesday, killing six. Palantir’s U.S. government and commercial revenue surged in the first quarter.
Why Grab Holdings Stock Is Back Under Pressure After a Big Q1 Beat

Why Grab Holdings Stock Is Back Under Pressure After a Big Q1 Beat

13 May 2026
Grab shares fell 1.1% to $3.60 in New York after first-quarter revenue beat estimates, rising 24% to $955 million. Profit jumped to $120 million from $10 million a year earlier. Investors weighed strong results against Indonesia’s new 8% ride-hailing commission cap. Grab kept its 2026 revenue and adjusted EBITDA outlook unchanged.
SoFi Bought a Key IPO Access Tool. The Stock Is Still Telling a More Cautious Story

SoFi Bought a Key IPO Access Tool. The Stock Is Still Telling a More Cautious Story

13 May 2026
SoFi acquired PrimaryBid’s technology to expand IPO access for retail investors, confirmed by both companies. SoFi shares fell 2.9% to $15.44 after Truist cut its price target, citing concerns over loan and technology platforms. The acquisition follows a drop in technology-platform accounts and comes as SoFi reported strong first-quarter revenue and member growth. Terms of the deal were not disclosed.

Popular

GitLab Layoffs Send Stock Lower as AI ‘Agentic Era’ Bet Tests Investor Patience

GitLab Layoffs Send Stock Lower as AI ‘Agentic Era’ Bet Tests Investor Patience

12 May 2026
GitLab Inc. will cut jobs and restructure global operations to fund artificial-intelligence agents, sending shares down 9.6% to $23.18 Tuesday. The company did not specify the number of roles affected. CEO Bill Staples said most savings will be reinvested, with details expected at the June 2 earnings call. Raymond James downgraded the stock, citing execution risks and slowing growth.
Go toTop